Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company's lead therapy is currently in a pivotal study in Alzheimer's Disease and was awarded FDA Breakthrough Device Designation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/22/23 | $73,000,000 | Series B |
Alzheimer's Drug Discovery Foundation FoundersX Ventures  IAG Capital Partners Starbloom Capital WS Investments | undisclosed |
